Search Within

Daniel C Danila

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Journal Article (14)
  2. Meeting Abstract (10)
Groups
  1. Department of Medicine (24)
  2. Genitourinary Oncology Service (24)
  3. Sloan Kettering Institute Postdocs (24)
  4. Solid Tumor Oncology Division (24)
  5. Hematologic Malignancies, Division of (18)
  6. GSK Faculty (16)

More Groups

People
  1. Michael Morris (21)
  2. Howard Scher (19)
  3. Susan Slovin (16)
  4. Dana Rathkopf (13)
  5. Wassim Abida (13)
  6. Philip Kantoff (11)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (1)
  4. 2022 (3)
  5. 2021 (3)
  6. 2020 (4)

More Years

Publications
  1. Journal of Clinical Oncology (8)
  2. Clinical Cancer Research (3)
  3. JCO Precision Oncology (3)
  4. Cancer Research (2)
  5. Journal of Nuclear Medicine (2)
  6. Cell (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (11)
  2. American Association for Cancer Research (5)
  3. Society of Nuclear Medicine (2)
  4. American Chemical Society (1)
  5. American Medical Association (1)
  6. Cell Press (1)

More Publishers

Results (24)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical, imaging, and technical factors associated with successful genomic profiling of bone biopsy tissue in prostate cancer
    Journal Article

    Ridouani, F.; Vargas, H. A.; Holzwanger, D. J.; Schòˆder, H.; Waters, E.; Petre, E. N.; Martin, A.; Satagopan, J.; Gonen, M.; Autio, K. A.; more...
    European Urology Oncology (2025)

    Fulltext@MSK | Save
  • Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer
    Journal Article

    Lenis, A. T.; Ravichandran, V.; Brown, S.; Alam, S. M.; Katims, A.; Truong, H.; Reisz, P. A.; Vasselman, S.; Nweji, B.; Autio, K. A.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Evaluating immune-related adverse events using PRO-CTCAE in a phase II study of ipilimumab for hormone-sensitive prostate cancer
    Journal Article

    Vargas P. de Almeida, D.; Anderson, J. M.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Cohn, E. D.; Baser, R. E.; Scher, H. I.; Autio, K. A.
    Journal of Immunotherapy and Precision Oncology (2023)

    Fulltext@MSK | Save
  • Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality
    Journal Article

    Keegan, N. M.; Vasselman, S. E.; Barnett, E. S.; Nweji, B.; Carbone, E. A.; Blum, A.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; more...
    Prostate (2022)

    Fulltext@MSK | Save
  • Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality
    Meeting Abstract

    Keegan, N. M.; Vasselman, S. E.; Barnett, E.; Nweji, B.; Carbone, E.; Blum, A.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors
    Journal Article

    Stopsack, K. H.; Nandakumar, S.; Arora, K.; Nguyen, B.; Vasselman, S. E.; Nweji, B.; McBride, S. M.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Bcl-2 inhibitor enhances anti-androgen therapy induced regression of castration sensitive prostate cancer
    Meeting Abstract

    Hirani, R.; Nandakumar, S.; Kalidindi, T.; Fidele, D.; Rajanala, H.; Mazzu, Y.; Yoshikawa, Y.; Jehane, L.; Lee, G. S. M.; de Stanchina, E.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Significance of targeting the antiapoptotic pathway in castration-sensitive prostate cancer
    Meeting Abstract

    Chakraborty, G.; Hirani, R.; Nandakumar, S.; Kalidindi, T. M.; Fidele, D.; Rajanala, S. H.; Mazzu, Y. Z.; Yoshikawa, Y.; Jehane, L. E.; Lee, G. S. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality in BRCA2-altered prostate tumors
    Journal Article

    Chakraborty, G.; Khan Patail, N.; Hirani, R.; Nandakumar, S.; Mazzu, Y. Z.; Yoshikawa, Y.; Atiq, M.; Jehane, L. E.; Stopsack, K. H.; Lee, G. S. M.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC)
    Meeting Abstract

    Vargas Pivato de Almeida, D.; Anderson, J.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Dayan, E. S.; Curley, T.; Arauz, G.; Baser, R. E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save